Currently, there is no FDA-approved vaccine against Yersinia pestis, the causative agent of bubonic and pneumonic plague. Since both humoral-and cell-mediated immunity are essential in providing protection to the host against plague, we developed a live-attenuated vaccine strain by deleting Braun lipoprotein (lpp) and plasminogen-activating protease (pla) genes from Y. pestis CO92. The ∆lpp/∆pla double isogenic mutant was highly attenuated in evoking both bubonic and pneumonic plague in a mouse model. Further, animals immunized with the mutant by either the intranasal or the subcutaneous routes were significantly protected from developing subsequent pneumonic plague. In mice, the mutant poorly disseminated to peripheral organs and the production of pro-inflammatory cytokines concurrently decreased. Histopathologically, reduced damage to the lungs and liver of mice infected with the ∆lpp/∆pla double mutant was observed when compared to the wild-type (WT) CO92-challenged animals. The ∆lpp/∆pla mutant-immunized mice elicited a humoral immune response to the WT bacterium, as well as to CO92-specific antigens. Moreover, T cells from the mutant-immunized animals exhibited significantly higher proliferative responses when stimulated ex vivo with the heat-killed WT CO92 antigens, compared to responses in mice immunized with the same sub-lethal dose of WT CO92. Likewise, T cells from the mutant-immunized mice produced more interferon (IFN)-γ and interleukin-4. These animals had an increasing number of tumor necrosis factor (TNF)-α-producing CD4 + and CD8 + T cells compared to WT CO92-infected mice. These data emphasized the role of TNF-α and IFN-γ in protecting mice against pneumonic plague. Overall, our studies provided evidence that deletion of lpp and pla genes acted synergistically in protecting animals against pneumonic plague, and we have demonstrated an immunological basis for this protection. 
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